Study design
This parallel, randomized, blank-controlled prospective clinical trial will be conducted at the Guangdong Provincial Hospital of Traditional Chinese Medicine in China. The trial design was in accordance with the Consolidated Standards for Reporting Trials (CONSORT 2010) guidelines and the Interventions for Reporting Standard Acupuncture Controlled Trials (STRICTA) [14]. We will enroll eligible inpatients who will undergo a colonoscopy and randomly allocate them in a 1:1 ratio to the intervention and control groups. The intervention group will receive auricular acupressure during bowel preparation, whereas the control group will not receive any intervention. Gut intolerance will be assessed immediately after bowel preparation. A flowchart of this trial is shown in Figure 1.
Participants
Inclusion criteria
Patients who are willing to participate in the trial and meet the following conditions will be included regardless of sex: those who will undergo a colonoscopy at our institution, those aged 18 to 70 years, and those who sign the informed consent form.
Exclusion criteria
Those who meet any of the following conditions will be excluded: suffering from severe mental disorder; exhibiting serious intestinal diseases; contraindications to colonoscopy; severe liver, kidney, heart, brain, lung dysfunction, or neurological diseases; intolerance to colonoscopy; menstrual cycle, pregnancy, or breastfeeding; allergy to drugs and other ingredients used in the trial; skin lesions at the to-be-treated auricular acupoints; or allergy to ear adhesive.
Recruitment and withdrawal
Eligible inpatients who satisfy the inclusion criteria will be recruited from the Guangdong Provincial Hospital of Traditional Chinese Medicine. All admitted patients who meet the initial eligibility criteria will be asked if they are willing to participate. Participants are permitted to withdraw at any time during the trial for any reason.
Sample size
According to the data from a preliminary study, the incidence of ADRs to bowel preparation was expected to be 60% in the control group and 34% in the intervention group. In line with the 1:1 parallel control principle, the PASS statistical analysis software package was used to calculate the sample size for a double-sided significance level of 0.05 and a power of 90% (α=0.05, β=0.1). Considering an expected 20% loss to follow-up, the sample size was determined to be 190 cases (n=95 in each group).
Randomization and blinding
Excel will be used to generate 190 random numbers with sizes ranging from 0 to 1, and assign sequence numbers based on the order of random numbers from 1 to 190, where odd number corresponds to control group and even number corresponds to ear point group. Make random numbers and sequence numbers into random cards and place them in an opaque envelope seal. A specifically appointed investigator will be responsible for randomization. After informed consent of the participants has been obtained and they have completed the baseline data collection, the allocation personnel will inform the acupuncturists of the allocation assignment.
Owing to the unique features of the intervention, we could only blind the examiners, data collectors, and statisticians but not the interveners or study participants. Before data collection, subjects in the intervention group will be asked to remove the auricular adhesives, which will be checked by the personnel in charge of randomization. During the entire study period, the participants and other researchers are not allowed to disclose the grouping to the endoscopists, data processors, or statisticians. To avoid communication between the two groups, the patients will be sent to separate wards. Thus, bias will be further reduced.
Intervention
Routine bowel preparation scheme
All participants were limited to low-residue foods the day before colonoscopy. All subjects will undergo identical bowel preparation and receive 3 bags of Compound PEG electrolyte powder (Ⅱ) (Shenzhen Wanhe pharmaceutical Co. Ltd., China, 68.56 g / bag, H20030827), each containing 1.46 g sodium chloride, 5.68 g anhydrous sodium sulfate, 0.74 g potassium chloride, 1.68 g sodium bicarbonate, and 59 g PEG 4000. Each PEG sachet will be diluted in 1 L of drinking water and consumed within 1 hour. Bowel preparation before colonoscopy will be performed in the morning and afternoon. Subjects scheduled for two different time slots will be instructed to drink 1 L of laxative solution at 8:00 p.m. before the day of colonoscopy. Subjects undergoing colonoscopy in the morning will drink the remaining 2 L from 4:00 to 6:00 a.m. on the day of the examination, whereas subjects undergoing colonoscopy in the afternoon will drink from 10:00 to 12:00 p.m. A bottle of simethicon (Berlin-Chemie AG, Germany; 30 ml/ bottle, HJ20160184) will be added to the last 1 L of the laxative. While taking laxatives, the study participants will be told to move around and massage the abdomen clockwise to promote defecation.
Intervention group
The subjects in the intervention group will be treated with auricular acupressure during bowel preparation. Before starting bowel preparation, auricular adhesives will be applied to particular spots on both ears. The product used for auricular acupressure will be Wangbuliuxingzi (Vaccaria seed) auricular adhesive (Hebei Heshi Medical Instrument Co., Ltd., China). The product information is shown in Figure 2. According to the clinical experience of our research group and the effective prescription published previously [16, 17], five acupoints [Cardia (CO3), Stomach (CO4), Large Intestine (CO7), Sympathetic Nerve (AH6), and Subcortex (AT4)] will be selected as the auricular acupoint protocols in this study. The localization of acupoints refers to the nomenclature and location of auricular acupoints [15] stipulated by the World Federation of Acupuncture-Moxibustion Societies (WFAS) in 2013. The anatomical locations are listed in Table 1 and illustrated in Figure 3. Since subjects need to drink a 3-L Split-dose of PEG solution and each 1 L laxative should be drunk within an hour to achieve a better quality of bowel cleansing, they will be asked to self-press the adhesives three times during each 1 L of laxative. Each acupoint should be pressed for at least 1 min per session, and the press should cause a distending and aching sensation within the subject’s tolerance. Medical staff will promptly remind and instruct the patient regarding the timing of the laxative.
If the adhesive falls off due to exercise, bathing, or other unexpected conditions, the researcher will reapply the plaster to the original spot. If skin abrasion or swelling occurs at the treated site, the subject must contact the acupuncturist immediately to treat it, which will be recorded in a case report form (CRF).
Control group
The subjects in the control group will not receive any supplementary means for ADR prevention but will receive only a routine bowel preparation scheme.
Colonoscopy procedures
All the colonoscopies will be performed by the same experienced endoscopist. Colon cleanliness will be assessed by the endoscopist and two experienced endoscopy nurses who are not involved in the trial. All three researchers will be blinded to the intervention allocation and will independently judge whether each colon had no staining, minor staining, or residual stool after the operation. The study nurse will register the majority consensus.
Outcome measures
The primary outcome measure will be the total incidence of abdominal pain, bloating, nausea, and vomiting after PEG intake. The secondary outcome measures will be (1) incidence of various ADRs: the proportion of each adverse event; and (2) corresponding score of various adverse events. The Likert scoring method will be used to score the degree of discomfort of the abdominal pain, abdominal distension, and nausea symptoms. For this scale, 0 means no discomfort, while 10 means unable to tolerate due to strong discomfort. Vomiting severity will be scored according to frequency. If the subject vomits once, it will be recorded as 2 points; if the subject vomits more than or equal to 4 times, it will be recorded as 10 points; (3) patients’ willingness to have the colonoscopy done again at this facility in the future will also be evaluated (yes or no); (4) procedure time: the procedure time is defined as the time spent drinking PEG (in minutes); (5) 100% PEG solution intake rate: does the patient take a complete laxative as ordered (yes or no); (6) qualified rate of bowel preparation: we use Boston Bowel Preparation Scale (BBPS) to assess efficacy in bowel preparation; the qualified rate of bowel preparation is defined as the ratio of subjects’ BBPS score of > 6 [18]; (7) adverse events of auricular acupressure: incidence of allergic reactions such as flushing, rash, exudation, and ulceration at the application site.
Safety assessment
Allergic reactions such as skin flushing, rash, exudation, and ulceration may occur during the treatment evaluation period. If an allergic reaction occurs, acupoint acupressure on the ear will be immediately stopped. Auricular acupressure-related adverse effects shall be recorded and addressed immediately.
Data collection
All baseline data for each participant will be collected before the start of the intervention. Baseline data will include sex, body mass index (BMI), past medical history, medication history, recent defecation, history of colorectal surgery, indications for colonoscopy, and gastrointestinal disorders before bowel preparation. To facilitate researchers in observing and recording various indicators, each subject's information will be recorded in the CRF, and codes and abbreviations will be used instead of names to protect privacy. Data in the CRF form will be independently entered and checked by two third-party data managers unrelated to the test to confirm authenticity, accuracy, and integrity. The participants’ medical records (study medical records, CRF, colonoscopy results, etc.) will be stored in the hospital. No public report of the results of this study will disclose the participants’ personal identities.
Quality control
To ensure the quality of this study, the trial underwent several changes and revisions by relevant digestive disease specialists, acupuncture experts, professional statisticians, and research methodologists. Strict inclusion and exclusion criteria were established. To maintain objectivity, we will ensure that the data collector statisticians and endoscopists will be blinded. All the researchers, particularly the auricular acupressure operators, completed our training, thereby ensuring consistent treatment practices and uniformity in the terminology used for communication with the subjects. The CRF will be meticulously completed in accordance with the CRF guidelines and checked by third-party data administrators unrelated to the trial to ensure the scientific accuracy of the data. If suspicious data is found, the researcher should be contacted and verified, and the data administrator will modify, confirm and enter the data according to the researcher's reply. All quality control documents shall be complete and filed as required.
Statistical analysis
SPSS (version 25.0) will be used for data processing. The measurement data will be expressed as means ± standard deviation or median (interquartile interval), and the counting data will be described by the number of cases (percentage). Data will be analyzed using the principle of intention-to-treat. That is, regardless of whether the subjects receive the treatment of the assigned group, they will be included in the allocated group for the statistical analysis of the curative effect. Efficacy and safety measures will be analyzed in accordance with “per-protocol”, whereby we will include all subjects who completed the entire trial and followed the protocol requirements. Fisher’s exact test or Pearson’s chi-square test will be used for trial group comparisons of the incidence of ADRs. Differences in quantitative data such as age, BMI, the score of various adverse events, and procedure time will be compared between the experimental and control groups using the t-test for comparison of two samples and the rank-sum test for non-normal distribution or unevenness of variance. All tests of effects will be conducted at a two-sided alpha level of 0.05.
Patient and public involvement
The patients will not be involved in the design or conduct of the study. However, patients who showed symptoms of bowel preparation intolerance in our clinical department were consulted before the trial design, and the selected auricular acupoints, treatment frequency, and duration of this trial were summarized based on our clinical experience and patient feedback.
Ethics statement
This study was approved by the Institutional Ethics Committee of the Guangdong Provincial Hospital of Traditional Chinese Medicine on 1st May 2022 (approval no. YF2022-093). Informed consent forms were developed in compliance with the Declaration of Helsinki (revised in 2013) [15] (supplementary 1). All qualified participants will be informed of the details of the study and required to sign written informed consent forms before participating. The results will be published in a peer-reviewed publication and presented at conferences.